High-Affinity Binding of Thyrotropin to the Extracellular Domain of Its Receptor Transfected in Chinese Hamster Ovary Cells

Thyroid ◽  
1993 ◽  
Vol 3 (2) ◽  
pp. 129-133 ◽  
Author(s):  
YUFEI SHI ◽  
MINJING ZOU ◽  
RANJIT S. PARHAR ◽  
NADIR R. FARID
1993 ◽  
Vol 139 (3) ◽  
pp. 425-429 ◽  
Author(s):  
K. Haraguchi ◽  
X. Peng ◽  
M. Kaneshige ◽  
E. Anzai ◽  
T. Endo ◽  
...  

ABSTRACT To determine whether thyrotrophin (TSH)-induced desensitization requires a thyroid-specific factor(s), the human TSH (hTSH) receptor was expressed in Chinese hamster ovary cells. The first incubation of the cells with TSH decreased the subsequent response of adenosine 3′,5′-cyclic monophosphate to freshly added TSH in the second incubation. This homologous desensitization was observed as early as after 3 h of the first incubation. The lowest dose of TSH that elicited desensitization was 0·1 nmol/l. The desensitization was not overcome by adding higher doses of TSH in the second incubation. A 125I-labelled TSH-binding study revealed a decrease in the number of high-affinity binding sites but not in that of low-affinity binding sites. The data suggest that TSH-induced desensitization in hTSH receptor-transfected cells is caused, at least in part, by a decrease in the number of TSH receptors on the cell surface. The evidence demonstrates, contrary to an earlier report, that a thyroid-specific factor(s) is not required for hTSH receptor desensitization. Journal of Endocrinology (1993) 139, 425–429


2014 ◽  
Vol 99 ◽  
pp. 50-57 ◽  
Author(s):  
Aleksandra Sokolowska-Wedzina ◽  
Aleksandra Borek ◽  
Julia Chudzian ◽  
Piotr Jakimowicz ◽  
Malgorzata Zakrzewska ◽  
...  

1995 ◽  
Vol 270 (8) ◽  
pp. 3958-3964 ◽  
Author(s):  
Michael Fountoulakis ◽  
Cecilia Mesa ◽  
Georg Schmid ◽  
Reiner Gentz ◽  
Michael Manneberg ◽  
...  

Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document